E. Rahal

Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitus tipo 2 no sistema de saúde suplementar do Brasil

OBJECTIVES: To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). METHODS: A discrete event simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY]) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. RESULTS: The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years, were R

Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.

10,850,185, R

Estimated hospitalizations attributable to Diabetes Mellitus within the public healthcare system in Brazil from 2008 to 2010: study DIAPS 79

14,836,265 and R

PDB101 Diaps 79: Estimated Hospitalizations Attributable to Diabetes Mellitus in Brazilian Public Health Care System (SUS) Between 2008-2010

14,679,099 for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower costs and greater effectiveness in both comparisons, with projected savings for the first three years of R

PCN21 Melody Brasil: Real World Health Outcomes of the Treatment of Metastatic Melanoma Patients in the Brazilian Health System

3,874 and R

PCV37 VIP Study: Incremental Cost During Hospitalization After Total Knee and Hip Arthroplasty in Brazilian Health Care Services

3,996, respectively. The BIM estimated cumulative savings of R

PCV103 Vip Brazil: Resource Use and Associated Costs of Thrombotic Events After Total Knee Replacement (TKR) Surgery in Brazilian Public Health Care System (SUS)

417,958 with the repayment of saxagliptine in three years from the perspective of a health plan with 1,000,000 covered individuals. CONCLUSION: From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon.

PCN79 IMPACT OF NON-ADHERENCE TO IMATINIB ON PROGRESSION-FREE SURVIVAL AS 1ST TREATMENT FOR CHRONIC MYELOID LEUKEMIA IN BRAZIL: TWO YEARS FOLLOW UP

OBJECTIVES To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). METHODS A discrete event simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY]) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. RESULTS The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years, were R

PCN122 MELODY BRAZIL: CHEMOTHERAPY CHOICES FOR PATIENTS WITH METASTATIC MELANOMA IN THE PUBLIC HEALTH CARE SYSTEM (SUS)

10,850,185, R

Avaliação de tecnologias em saúde (ATS): um guia prático para gestores

14,836,265 and R